TD Asset Management Inc Has $379.25 Million Holdings in Gilead Sciences, Inc. $GILD

Key Points

• TD Asset Management Inc increased its stake in Gilead Sciences by 44.7%, owning approximately $379.25 million worth of the company's stock as of its latest SEC filing.
• Several Wall Street analysts upgraded Gilead Sciences' ratings, with price targets ranging from $128 to $135, reflecting positive outlooks for the biopharmaceutical company.
• Gilead Sciences declared a quarterly dividend of $0.79, resulting in an annualized yield of 2.7%, with a current dividend payout ratio of 62.95%.

TD Asset Management Inc increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 44.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,420,676 shares of the biopharmaceutical company's stock after buying an additional 1,056,474 shares during the quarter. TD Asset Management Inc owned approximately 0.27% of Gilead Sciences worth $379,250,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Smallwood Wealth Investment Management LLC bought a new stake in Gilead Sciences in the 1st quarter valued at $25,000. Activest Wealth Management raised its stake in Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 227 shares during the period. Goodman Advisory Group LLC bought a new stake in Gilead Sciences in the 1st quarter valued at $29,000. Colonial Trust Advisors raised its stake in Gilead Sciences by 304.3% in the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 213 shares during the period. Finally, Core Alternative Capital raised its stake in Gilead Sciences by 370.8% in the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 241 shares during the period. Institutional investors own 83.67% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Needham & Company LLC upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a research note on Friday, July 25th. Daiwa Capital Markets upgraded Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price objective on the stock in a research report on Tuesday, August 19th. Daiwa America upgraded Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Cantor Fitzgerald increased their price objective on Gilead Sciences from $129.00 to $135.00 and gave the stock an "overweight" rating in a research report on Thursday, October 9th. Finally, Truist Financial upgraded Gilead Sciences from a "hold" rating to a "buy" rating and increased their price objective for the stock from $108.00 to $127.00 in a research report on Friday, August 8th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $118.08.

Gilead Sciences Stock Up 0.9%

Shares of NASDAQ GILD opened at $118.21 on Tuesday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. Gilead Sciences, Inc. has a 52 week low of $84.34 and a 52 week high of $121.83. The stock has a market capitalization of $146.68 billion, a P/E ratio of 23.55, a PEG ratio of 0.80 and a beta of 0.34. The stock's fifty day moving average is $114.72 and its 200 day moving average is $110.30.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.08 billion for the quarter, compared to analysts' expectations of $6.95 billion. During the same quarter last year, the business earned $2.01 earnings per share. Gilead Sciences's revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were given a $0.79 dividend. The ex-dividend date was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. Gilead Sciences's dividend payout ratio (DPR) is presently 62.95%.

Insider Buying and Selling

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $113.63, for a total value of $1,136,300.00. Following the transaction, the chief executive officer owned 595,725 shares in the company, valued at approximately $67,692,231.75. This trade represents a 1.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the sale, the insider directly owned 114,168 shares in the company, valued at $13,532,333.04. This trade represents a 19.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 66,000 shares of company stock worth $7,632,100. Company insiders own 0.27% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.